Latest Operating Expenses News

Winsome Resources has filed a key Technical Report for its Adina Lithium Project and extended payment terms for the Renard Operation acquisition, marking significant progress in project development and regulatory engagement.

BetMakers Technology Group reports a sharp 69% reduction in adjusted EBITDA loss and a 43% improvement in operating cash flow for Q2 FY25, marking a pivotal shift from restructuring to growth. The company’s successful Apollo platform migration and cost-cutting initiatives underpin a confident outlook for revenue expansion.

archTIS Limited reported a 12% increase in annual recurring revenue to $4 million and achieved net positive cash flow from operations, while signing a binding term sheet to acquire Direktiv’s assets, signaling strategic growth in data-centric security.

Native Mineral Resources Holdings Limited reported a net cash outflow for the December quarter, offset by a $4.1 million entitlement offer and additional funding commitments to sustain exploration activities.

GreenHy2 Limited reports a slight cash decline but strengthens its foothold in renewable energy with key partnerships and strategic pivots in hydrogen storage technology.

Fluence Corporation Limited reported a net cash outflow of US$3.03 million for the December 2024 quarter, maintaining liquidity with nearly US$9 million in cash and expanded credit facilities.

Adherium reports strong patient adoption and new US partnerships, positioning for significant expansion in 2025 with a target of 9,000 active users and entry into the Pharmacy Benefit Management sector.

Mach7 Technologies reports a robust Q2 FY25 with a 15.6% increase in Contracted Annual Recurring Revenue, reaffirming its FY25 growth guidance and initiating a $5 million share buy-back.

PainChek Ltd reports robust growth with 100,000 contracted licences globally and positive FDA clearance progress, alongside a promising launch of its Infant App targeting a vast new market.

Omni Bridgeway Limited reports strong investment proceeds and new commitments in the first half of FY25, alongside significant cost savings and the imminent financial close of Fund 9 with Ares Management.

Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.

Zelira Therapeutics has secured a fourth funding tranche of US$681,000, advancing its HOPE® Autism Spectrum Disorder FDA trial process and bringing total funding to US$3.25 million. The company is progressing clinical validation and product development, including the transformation of Zenivol® into a capsule formulation.